Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Laura Biernat"'
Autor:
Daniel W. Visscher, Larry Tait, Nat L. Pernick, Judith Abrams, Malathy P.V. Shekhar, Laura Biernat
Publikováno v:
Medical Oncology. 27:466-473
Neoadjuvant chemotherapy is a standard therapy for patients with locally advanced breast cancer (LABC) and is increasingly used for early stage operable breast cancer. Not all patients benefit from it, and reliable markers for predicting response are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3e83020f4cd7ad434cdd5fea65e93d
https://doi.org/10.1007/s12032-009-9235-7
https://doi.org/10.1007/s12032-009-9235-7
Autor:
Philip A. Philip, Patricia LoRusso, David L. Bouwman, Laura Biernat, Michael S. Simon, Kelly Vereeke, Deanna Stephens, Judith Abrams, Priya Vishnubhotla, Lawrence E. Flaherty, Lata Chandi Thatai
Publikováno v:
American Journal of Clinical Oncology. 29:484-489
Objective The primary aim of this study was to estimate the rate of clinical and pathologic response to preoperative docetaxel, doxorubicin, and infusional 5-fluorouracil in patients with locally advanced breast cancer. Secondary objective included t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ffcc5d48ef049bfa9139da70f536d4b
https://doi.org/10.1097/01.coc.0000231439.42503.44
https://doi.org/10.1097/01.coc.0000231439.42503.44
Autor:
John D. Crissman, Fazlul H. Sarkar, Laura Biernat, Roger Kucway, Vainutis K. Vaitkevicius, Kanwal Singh, Wei Du, Sanaa T. Dergham, Michael C. Dugan
Publikováno v:
Pancreas. 14:229-236
HER-2/neu expression in pancreatic adenocarcinoma has been inconsistently reported and has not been fully evaluated with respect to histologic grade and tumor grade heterogeneity. We studied HER-2/neu expression in a series of 79 primary pancreatic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4f20256016a886f999e4098dc27dfc0
https://doi.org/10.1097/00006676-199704000-00003
https://doi.org/10.1097/00006676-199704000-00003
Autor:
Judith Sebolt, Janet Dzubow, Laura Biernat, Wilbur R. Leopold, Gregory M. L. Patterson, Loretta Lisow, Robert B. Perni, Lynne Jones, Sarpotdar Pramod P, J. C. Knight, Susan A. Coughlin, Mark P. Wentland, Lisa Demchik, Nancy Lowichik, Gary Liversidge, Fred Valeriote, Manuel Valdivieso, Susan Pugh, Antoinette J. Wozniak, Julie Jones, Patricia LoRusso, Marie Christine Bissery, Lisa Polin, Brenda J. Foster, Chiab Panchapor, Bruno Joseph A, Thomas H. Corbett, Lawrence H. Baker, J Michael Shaw, Ken C. Mattes, Elaine Liversidge, Richard E. Moore, James B. Rake, Kathryn White
Publikováno v:
International Journal of Pharmacognosy. 33:102-122
Each independently arising tumor is a separate and unique biologic entity with its own unique histologic appearance, biologic behavior, and drug response profile. Thus, in drug discovery, no single tumor has been a perfect predictor for any other tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::195219885471309e7650f952087a4926
https://doi.org/10.3109/13880209509067092
https://doi.org/10.3109/13880209509067092
Autor:
Kenneth C. Mattes, Chiab Panchapor, Patricia LoRusso, Susan A. Coughlin, Lance K. Heilbrun, James B. Rake, Kathryn White, Mark P. Wentland, Thomas H. Corbett, Jui Wanna Knight, Brenda J. Foster, Laurence H. Baker, Lisa Demchik, Lisa Polin, Fred Valeriote, Nancy Lowichik, Julie Jones, Lynne Jones, Susan Pugh, Ronald G. Powles, Robert Bruno Perni, Allan G. Hlavac, Laura Biernat
Publikováno v:
Expert Opinion on Investigational Drugs. 3:1281-1292
WIN33377 (Sterling/Kodak) entered Phase I clinical trials in 1994. The dose limiting toxicity has not been reached with completion of the 225 mg/m2 level, Q28 day schedule. To date, the agent has been very well tolerated with no evidence of liver tox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::845f1750180724f55c35dd4d4832fe7c
https://doi.org/10.1517/13543784.3.12.1281
https://doi.org/10.1517/13543784.3.12.1281
Publikováno v:
The breast journal. 6(4)
Fas and Fas ligand (FasL) mediate T-lymphocyte cytotoxicity and may also induce physiologic apoptosis in breast epithelium associated with menstruation and cessation of lactation. Altered expression may thus be associated with breast carcinoma progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::540883b76e3e27acb19e91fae580c52e
https://pubmed.ncbi.nlm.nih.gov/11348371
https://pubmed.ncbi.nlm.nih.gov/11348371
Autor:
Ken C. Mattes, Cavanaugh Paul Francis, Thomas H. Corbett, Antoinette Wozniak, Loretta Lisow, Susan Pugh, Sandra Essenmacher, Marie-Christine Bissery, Sandra Biggar, James B. Rake, Darrell Looney, Chiab Panchapor, Kathryn White, Lisa Polin, Frederick A. Valeriote, Scott C. Blair, Laurence H. Baker, Kerry Palmer, Lynne Jones, Laura Biernat, J. C. Knight, Nancy Lowichik, Lentawn Knight, Lisa Demchik, Daniel Polin, Julie Jones, Patricia LoRusso
Publikováno v:
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development ISBN: 9781461365488
The history of antitumor drug discovery has essentially been the use of two lymphocytic leukemias of mice as selection funnels through which all agents needed to pass in order to advance toward clinical development (L1210 prior to 1975 and P388 after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a80c4d0c5f75630557ec8287f948e65d
https://doi.org/10.1007/978-1-4615-3492-1_3
https://doi.org/10.1007/978-1-4615-3492-1_3
Publikováno v:
Investigational new drugs. 8(3)
Datelliptium acetate (NSC 311152) is a water soluble analogue of ellipticine. It is a solid tumor selective compound. In vitro, in a disk diffusion, soft agar colony formation assay (25 micrograms/disk), the compound demonstrated solid tumor selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0459b87ffa75353a97d60a6104c3e4cf
https://pubmed.ncbi.nlm.nih.gov/2177044
https://pubmed.ncbi.nlm.nih.gov/2177044
Autor:
Darlene W. Mood, Wei Du, Virginia Hill Rice, Christine Rymal, Prathima Koppolu, Wenlian Wang, Lynn Hryniuk, Jirair K. Bedoyan, Laura Biernat, Amr Aref, Mary Ann Kosir, Shakeela Shakoor, Laurel L. Northouse, L. L. Darga
Publikováno v:
Journal of Surgical Research. 96:304
Background. Studies of lymphedema have used inconsistent measures and criteria. The purpose of this pilot study was to measure the onset and incidence of acute lymphedema in breast cancer survivors using strict criteria for limb evaluation. Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8adeba5614246f8389dd24fd570844b8
https://doi.org/10.1006/jsre.2001.6123
https://doi.org/10.1006/jsre.2001.6123